Investigational drug · Phase 3
Ianalumab
Also called: VAY736, VAY736 AI
Not approved by FDA. In 18 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
18
16 still active
All registered trials
35
Any phase or sponsor naming "Ianalumab"
First trial start
2019
Feb 27, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ianalumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Immune Thrombocytopenia (ITP)
- Systemic Lupus Erythematosus
- Sjogren Syndrome
- Lupus Nephritis
- Sjogrens Syndrome
- Diffuse Cutaneous Systemic Sclerosis
- Sjögren´s Disease
- Primary Immune Thrombocytopenia
- Sjögrens Disease
- Rheumatoid Arthritis
Approved drugs for the same conditions: Immune thrombocytopenia · Rheumatoid arthritis · Lupus (SLE) · Hematology and blood cancers · Cardiovascular and metabolic · Immunology and inflammation · Rare and genetic disease · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Ianalumab" as an intervention, largest first.
- A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05985915 · 612 participants · Start Oct 27, 2023 · Primary completion Apr 22, 2033
Drug: Ianalumab (VAY736) · For: Sjogrens Syndrome
Sites: Fullerton, California; La Palma, California; Van Nuys, California · 198 sites in all
- Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom BurdenPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07621809 · 570 participants (planned) · Start Jul 16, 2026 · Primary completion Aug 15, 2029
Drug: VAY736; Placebo · For: Sjögren´s Disease
Sites: Peoria, Arizona; Searcy, Arkansas; Van Nuys, California · 72 sites in all
- Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06133972 · 550 participants (planned) · Start May 21, 2024 · Primary completion Apr 3, 2034
Drug: Placebo; Ianalumab · For: Systemic Lupus Erythematosus
Sites: Anniston, Alabama; Burbank, California; La Palma, California · 167 sites in all
- Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromePivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05349214 · 506 participants · Start Aug 4, 2022 · Primary completion May 13, 2025
Drug: VAY736 · For: Sjogren Syndrome
Sites: Fullerton, California; La Palma, California; Brandon, Florida · 146 sites in all
- Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus NephritisPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05126277 · 452 participants · Start Jul 14, 2022 · Primary completion Sep 21, 2027
Drug: ianalumab s.c. q4w; ianalumab s.c. q12w and 1 more · For: Lupus Nephritis
Sites: Birmingham, Alabama; La Palma, California; Orange, California · 145 sites in all
- Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05639114 · 436 participants · Start Mar 2, 2023 · Primary completion Mar 26, 2027
Drug: Ianalumab; Placebo · For: Systemic Lupus Erythematosus
Sites: Anniston, Alabama; Burbank, California; La Jolla, California · 135 sites in all
- Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06711887 · 348 participants (planned) · Start May 19, 2025 · Primary completion Aug 1, 2035
Drug: Ianalumab · For: Lupus Nephritis
Sites: Orchard Park, New York; Vitória, Brazil; Salvador, Brazil · 53 sites in all
- Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05624749 · 288 participants · Start Apr 21, 2023 · Primary completion Apr 12, 2027
Drug: ianalumab; placebo · For: Systemic Lupus Erythematosus
Sites: Anniston, Alabama; La Palma, California; Los Angeles, California · 90 sites in all
- Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromePivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT05350072 · 275 participants · Start Jul 28, 2022 · Primary completion May 7, 2025
Drug: VAY736 · For: Sjogren Syndrome
Sites: Van Nuys, California; Tamarac, Florida; Indianapolis, Indiana · 77 sites in all
- Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03827798 · 248 participants · Start Feb 27, 2019 · Primary completion Dec 4, 2024
Drug: CFZ533; Placebo to CFZ533 and 9 more · For: Hidradenitis Suppurativa
Sites: Clearwater, Florida; Orange Park, Florida; Tampa, Florida · 36 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Ianalumab reduces Sjögren disease activity.
Onuora S · Nat Rev Rheumatol 2026
- Update on biologics in SLE.
Delai M, Kyttaris VC · Curr Opin Rheumatol 2026
- Ianalumab in Sjögren's Disease - A First Step.
Negrini S · N Engl J Med 2026
- Ianalumab for the Treatment of Patients with Sjögren's Disease.
Mariette X, Grader-Beck T, Finzel S, et al. · N Engl J Med 2026
- Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab.
Ahuja R, Murrell D · J Eur Acad Dermatol Venereol 2026
- Immunosuppressive and immunomodulatory therapies in Sjögren's disease: current landscape and future perspectives.
Yazisiz V · Expert Opin Pharmacother 2026
Also in development for Primary Immune Thrombocytopenia (ITP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.